行情

SLNO

SLNO

SOLENO THERAPEUT
NASDAQ

实时行情|Nasdaq Last Sale

0.3350
+0.0047
+1.42%
交易中 15:21 01/27 EST
开盘
0.3600
昨收
0.3303
最高
0.3600
最低
0.3022
成交量
14.27万
成交额
--
52周最高
3.360
52周最低
0.2722
市值
2,673.52万
市盈率(TTM)
-0.8636
分时
5日
1月
3月
1年
5年
Soleno Therapeutics gets FDA update on DCCR program for Prader-Willi Syndrome
Soleno Therapeutics (SLNO -3.5%) received meeting minutes from the U.S. Food and Drug Administration (FDA) regarding the development of once-daily DCCR (diazoxide choline) extended-release tablets to treat Prader-Willi syndrome (PWS) PWS
Seekingalpha · 3天前
Soleno Concludes Type C Meeting With FDA For Diazoxide Choline In Prader-Willi Syndrome
Soleno Therapeutics Inc (NASDAQ: SLNO) said that on January 20, 2022, the Company 
Benzinga · 3天前
Soleno Therapeutics Provides Regulatory Update On DCCR For The Treatment Of Prader-Willi Syndrome
Soleno Therapeutics, Inc. (Soleno or the Company) (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided an update following recent
Benzinga · 3天前
Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome
REDWOOD CITY, Calif., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno or the Company) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided an update ...
GlobeNewswire · 3天前
Soleno Therapeutics to Participate in the LifeSci Partners 11th Annual Corporate Access Event
REDWOOD CITY, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, ...
GlobeNewswire · 01/05 13:00
Down 13.9% in 4 Weeks, Here's Why Soleno Therapeutics, Inc. (SLNO) Looks Ripe for a Turnaround
Soleno Therapeutics, Inc. (SLNO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a ...
Zacks · 2021/11/24 15:00
Soleno Therapeutics 宣布根据纳斯达克上市规则 5635(c)(4) 进行诱导性赠款
REDWOOD CITY, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare disease, today announced, as required by Nasdaq St...
GlobeNewswire · 2021/11/19 21:05
BRIEF-Soleno Therapeutics Q3 Loss Per Share $0.10
reuters.com · 2021/11/11 00:05
更多
财务预测
实际值（美元）
预测值（美元）
利润表更多
净利润（美元）
同比（%）
资产负债表更多
总资产（美元）
总负债（美元）
资产负债率（%）
现金流表更多
经营现金流（美元）
同比（%）
了解SLNO最新的财务预测，通过SLNO每股收益，每股净资产，每股现金流等数据分析SOLENO THERAPEUT近期的经营情况，然后做出明智的投资选择。
分析师评级

2位分析师的综合评级

强力推荐

免责声明：分析师观点仅供投资者决策参考，不构成任何买卖投资建议。

50.00%强力推荐
50.00%买入
0.00%中性
0.00%落后大盘
0.00%卖出
目标价格预测
分析师预测SLNO价格均价为6.00，最高价位7.00，最低价为5.00。
最高7.00
均价6.00
最低5.00
现价0.3350
EPS
实际EPS
预期EPS
-0.11-0.08-0.06-0.03
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
机构持股
总机构数: 57
机构持股: 2,961.97万
持股比例: 37.11%
总股本: 7,980.65万
类型机构数股数
增持
9
65.64万
建仓
5
75.10万
减持
10
59.05万
平仓
13
103.07万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
-2.44%
制药与医学研究
+0.53%
高管信息
Non-Executive Chairman/Independent Director
Ernest Mario
President/Chief Executive Officer/Chief Operating Officer/Director
Anish Bhatnagar
Chief Financial Officer
James Mackaness
Vice President
Patricia Hirano
Vice President
Kristen Yen
Independent Director
William Harris
Independent Director
Gwen Melincoff
Independent Director
Andrew Sinclair
Independent Director
Birgitte Volck
暂无数据
  • 全部
  • 财务报告
  • 内部人交易
更多
SLNO 简况
Soleno Therapeutics Inc是一家临床阶段的生物制药公司。该公司专注于治疗罕见疾病的疗法的开发和商业化。该公司主要药物二氮嗪胆碱控释片（DCCR）是一种有效的ATP敏感钾（KATP）通道激活剂。DCCR 以大脑、胰腺和脂肪组织为靶点的作用模式有可能广泛影响复杂的疾病，如普拉德-威利综合征（PWS），以降低食欲、减少觅食、改善饱腹感、改善胰岛素和瘦素抵抗并减少体脂。在PWS这样的条件下的许多有问题的行为可能将过度进食驱动作为根本原因，因此可以通过解决过度进食来改善。在美国和欧盟，该公司拥有PWS中DCCR的快速通道称号和该药物的孤儿药称号。

微牛提供Soleno Therapeutics Inc(NASDAQ-SLNO)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的SLNO股票新闻，以帮助您做出投资决策。

模拟交易：模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易SLNO股票基本功能。